Medline (NASDAQ:MDLN) Releases Earnings Results

Medline (NASDAQ:MDLN) posted its earnings results on Wednesday. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.18, FiscalAI reports. The company had revenue of $7.68 billion for the quarter.

Here are the key takeaways from Medline’s conference call:

• Second-quarter sales rose 12% to $7.7 billion, led by 16% growth in Supply Chain Solutions and 15% growth in U.S. acute care. Medline raised its full-year organic sales outlook to 9%-10% from 8.5%-9.5%.
• New customer signings exceeded $650 million in the first half, putting Medline ahead of pace for its $1 billion annual goal. Management cited strong opportunities across acute and non-acute care, including the expanded Allina Health partnership.
• Full-year adjusted EBITDA guidance was lowered to $3.3 billion-$3.4 billion from $3.5 billion-$3.6 billion, despite the sales outlook increase. Headwinds include operational investments, quality remediation, retail softness, Middle East-related inflation and costs from the Tracy warehouse fire.
• The Tracy fire reduced first-half net income by $336 million, with another $50 million-$100 million of related costs expected in the second half. Medline also expects quality remediation and delayed product reintroductions, including CHG wipes, to pressure earnings.
• Medline reported $920 million of first-half free cash flow and reduced net leverage to 2.9 times, meeting its long-term goal of below three times. The company is expanding and automating its California distribution footprint, which management expects to improve supply-chain resilience over time.

Medline Stock Up 2.1%

NASDAQ:MDLN traded up $0.72 on Friday, hitting $35.23. The stock had a trading volume of 8,254,832 shares, compared to its average volume of 7,366,242. The company has a quick ratio of 2.51, a current ratio of 4.41 and a debt-to-equity ratio of 0.65. Medline has a 52 week low of $32.81 and a 52 week high of $50.88. The business’s fifty day moving average is $38.24 and its 200 day moving average is $41.77. The company has a market cap of $46.28 billion and a PE ratio of 110.09.

Insider Activity at Medline

In other news, insider Jessi L. Corcoran bought 5,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were bought at an average cost of $34.15 per share, for a total transaction of $170,750.00. Following the acquisition, the insider directly owned 5,000 shares in the company, valued at approximately $170,750. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Douglas P. Golwas sold 100,000 shares of Medline stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $36.77, for a total transaction of $3,677,000.00. Following the completion of the sale, the insider directly owned 23,899 shares of the company’s stock, valued at approximately $878,766.23. The trade was a 80.71% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.81% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Mass General Brigham Inc bought a new position in shares of Medline during the fourth quarter valued at about $1,104,000. Sumitomo Mitsui Trust Group Inc. bought a new stake in Medline in the 1st quarter worth about $1,177,000. Baillie Gifford & Co. bought a new stake in Medline in the 4th quarter worth about $437,236,000. Massachusetts Financial Services Co. MA purchased a new stake in Medline in the 4th quarter valued at about $429,544,000. Finally, UBS Group AG bought a new position in shares of Medline during the 4th quarter worth approximately $54,707,000.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported second-quarter earnings of $0.50 per share, exceeding the $0.32 analyst consensus, while revenue reached $7.69 billion. The company also raised its 2026 organic-sales growth forecast to 9%–10%, signaling continued demand for its medical products. Medline Q2 Earnings Snapshot Medline Raises 2026 Organic Sales Outlook
• Positive Sentiment: BTIG reiterated a Buy rating and $55 price target, citing robust growth and viewing current headwinds as transitory. At that target, the shares would have substantial potential upside from recent trading levels. BTIG Medline Rating
• Neutral Sentiment: Truist lowered its price target from $56 to $47, and Stifel reduced its target from $50 to $45, but both firms maintained Buy ratings. The target cuts reflect increased caution, while the continued recommendations indicate analysts still see meaningful long-term upside. Truist Price Target Update Stifel Price Target Update
• Negative Sentiment: Medline lowered its 2026 adjusted EBITDA forecast to $3.3 billion–$3.4 billion despite the sales outlook increase. The weaker profit guidance has weighed on the stock because it suggests margin pressure or higher costs and offsets the quarterly earnings beat. Medline Falls After EBITDA Outlook Cut
• Negative Sentiment: Several law firms, including Kaplan Fox and Kessler Topaz, announced investigations into potential securities-law violations involving Medline. The actions follow an FDA warning letter reportedly identifying significant violations. These announcements create legal, regulatory and reputational risks, although the investigations do not establish wrongdoing. Kaplan Fox Medline Investigation Kessler Topaz Medline Investigation

Analyst Upgrades and Downgrades

MDLN has been the topic of several recent research reports. Robert W. Baird set a $42.00 price objective on Medline in a report on Thursday. Weiss Ratings downgraded Medline from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, July 23rd. BMO Capital Markets reissued an “outperform” rating and set a $47.00 price target on shares of Medline in a research note on Thursday. Stifel Nicolaus reduced their price target on Medline from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Deutsche Bank Aktiengesellschaft set a $37.00 price objective on Medline in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $48.50.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.